Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone.
The patient was 54-year-old woman diagnosed as recurrent invasive thymoma (type B3; WHO classification). Although partial response was obtained by systemic chemotherapy (PAC: cisplatin, doxorubicin, cyclophosphamide), the tumor started to become enlarged after cessation of chemotherapy. Combined treatment of octreotide and prednisolone was administrated because various chemotherapies, including PAC, were not effective. After seven months, the tumor size was markedly decreased. The combination of octreotide and prednisolone should be considered as one of the choices of treatment in patients with recurrent thymoma.
Ito
Jun
J
Department of Respiratory Medicine, Juntendo University, School of Medicine, Tokyo.
Sekiya
Mitsuaki
M
Miura
Kayo
K
Yoshimi
Kaku
K
Suzuki
Tsutomu
T
Seyama
Kuniaki
K
Izumi
Hiroshi
H
Uekusa
Toshimasa
T
Takahashi
Kazuhisa
K
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D015282:Octreotide / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives*; D013945:Thymoma / Q000188:drug therapy*; D013953:Thymus Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013004:Somatostatin; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D002945:Cisplatin; D015282:Octreotide